JP2005511644A - 核酸およびカチオン性アミノグリコシドの組成物ならびにそれを使用および調製する方法 - Google Patents

核酸およびカチオン性アミノグリコシドの組成物ならびにそれを使用および調製する方法 Download PDF

Info

Publication number
JP2005511644A
JP2005511644A JP2003547414A JP2003547414A JP2005511644A JP 2005511644 A JP2005511644 A JP 2005511644A JP 2003547414 A JP2003547414 A JP 2003547414A JP 2003547414 A JP2003547414 A JP 2003547414A JP 2005511644 A JP2005511644 A JP 2005511644A
Authority
JP
Japan
Prior art keywords
nucleic acid
composition
cationic
aminoglycoside
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003547414A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005511644A5 (enExample
Inventor
イゴール ゴンダ
ディーパ デッシュパンデ
Original Assignee
アラダイム コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アラダイム コーポレーション filed Critical アラダイム コーポレーション
Publication of JP2005511644A publication Critical patent/JP2005511644A/ja
Publication of JP2005511644A5 publication Critical patent/JP2005511644A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2003547414A 2001-11-21 2002-11-15 核酸およびカチオン性アミノグリコシドの組成物ならびにそれを使用および調製する方法 Pending JP2005511644A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/990,181 US20030096774A1 (en) 2001-11-21 2001-11-21 Compositions of nucleic acids and cationic aminoglycosides and methods of using and preparing the same
PCT/US2002/036529 WO2003045965A2 (en) 2001-11-21 2002-11-15 Compositions of nucleic acids and cationic aminoglycosides and methods of using and preparing the same

Publications (2)

Publication Number Publication Date
JP2005511644A true JP2005511644A (ja) 2005-04-28
JP2005511644A5 JP2005511644A5 (enExample) 2006-03-23

Family

ID=25535873

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003547414A Pending JP2005511644A (ja) 2001-11-21 2002-11-15 核酸およびカチオン性アミノグリコシドの組成物ならびにそれを使用および調製する方法

Country Status (6)

Country Link
US (2) US20030096774A1 (enExample)
EP (1) EP1453845A4 (enExample)
JP (1) JP2005511644A (enExample)
AU (1) AU2002363928A1 (enExample)
CA (1) CA2467677A1 (enExample)
WO (1) WO2003045965A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009536612A (ja) * 2006-04-06 2009-10-15 トランセイブ， インク． 脂質を用いた薬物製剤の高速送達とその処置方法
WO2016025627A1 (en) * 2014-08-12 2016-02-18 The Regents Of The University Of California Multifunctional membrane-active aminoglycoside-peptide conjugates

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
PT1458360E (pt) * 2001-12-19 2011-07-13 Novartis Ag Derivados de indole como agonistas do recetor s1p1
JP2005530704A (ja) * 2002-03-05 2005-10-13 トランセイブ， インク． 細胞内感染を予防及び治療するための吸入システム
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
PT1581236E (pt) * 2002-10-29 2013-12-24 Insmed Inc Libertação prolongada de anti-infecciosos
WO2005060573A2 (en) * 2003-12-15 2005-07-07 University Of Medicine And Dentistry Of New Jersey Pna-neamine conjugates and methods for producing and using the same
US20080226605A1 (en) * 2005-05-19 2008-09-18 Dev Priya Arya Methods and Compositions Facilitating Entry of Compounds Into Cells
EP3067047B1 (en) 2005-12-08 2022-04-20 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections
CA2885621C (en) * 2007-03-30 2016-01-05 Hirofumi Takeuchi Transpulmonary liposome for controlling drug arrival
WO2008137717A1 (en) 2007-05-04 2008-11-13 Transave, Inc. Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
US9789194B2 (en) 2007-11-27 2017-10-17 Rutgers, The State University Of New Jersey Graft copolymer polyelectrolyte complexes for drug delivery
US9271933B2 (en) * 2007-11-27 2016-03-01 Rutgers, The State University Of New Jersey Graft copolymer polyelectrolyte complexes for drug delivery
US8979797B2 (en) * 2010-12-16 2015-03-17 Ams Research Corporation High pressure delivery system and method for treating pelvic disorder using large molecule therapeutics
PL2852391T3 (pl) 2012-05-21 2022-04-11 Insmed Incorporated Układy do leczenia infekcji płuc
US10124066B2 (en) 2012-11-29 2018-11-13 Insmed Incorporated Stabilized vancomycin formulations
CN103272238B (zh) * 2013-06-08 2015-04-15 北京大学 基于dna与氨基糖苷类分子复合物的生物材料
LT3466432T (lt) 2014-05-15 2020-12-28 Insmed Incorporated Būdai, skirti plaučių netuberkuliozinėms mikobakterinėms infekcijoms gydyti
EP3773505B1 (en) 2018-03-30 2026-04-29 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
JP7449275B2 (ja) 2018-05-02 2024-03-13 インスメッド インコーポレイテッド リポソーム薬物製剤の製造方法
DE102018113243A1 (de) 2018-06-04 2019-12-05 BIOCHEM Zusatzstoffe Handels- und Produktionsgesellschaft mbH Verfahren zur Herstellung einer Zusammensetzung enthaltend zumindest eine Metall-Aminosäure-Verbindung sowie Zusammensetzung erhältlich durch ein derartiges Verfahren

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4400375A (en) * 1981-11-23 1983-08-23 Eli Lilly And Company Tobramycin-double stranded RNA complex suitable for inducing interferon
US5469854A (en) * 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5756353A (en) * 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
WO1994011384A1 (en) * 1992-11-13 1994-05-26 Immunex Corporation Novel cytokine designated elk ligand
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US6070575A (en) * 1998-11-16 2000-06-06 Aradigm Corporation Aerosol-forming porous membrane with certain pore structure

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009536612A (ja) * 2006-04-06 2009-10-15 トランセイブ， インク． 脂質を用いた薬物製剤の高速送達とその処置方法
WO2016025627A1 (en) * 2014-08-12 2016-02-18 The Regents Of The University Of California Multifunctional membrane-active aminoglycoside-peptide conjugates

Also Published As

Publication number Publication date
US20050019926A1 (en) 2005-01-27
AU2002363928A1 (en) 2003-06-10
US20030096774A1 (en) 2003-05-22
EP1453845A2 (en) 2004-09-08
CA2467677A1 (en) 2003-06-05
EP1453845A4 (en) 2005-11-09
AU2002363928A8 (en) 2003-06-10
WO2003045965A3 (en) 2004-01-08
WO2003045965A2 (en) 2003-06-05

Similar Documents

Publication Publication Date Title
JP2005511644A (ja) 核酸およびカチオン性アミノグリコシドの組成物ならびにそれを使用および調製する方法
Rolland From genes to gene medicines: recent advances in nonviral gene delivery
US20020012998A1 (en) Cationic liposomes
AU699162B2 (en) Cationic lipid:DNA complexes for gene targeting
CA2516188C (en) Chitosan-derivatives for gene delivery and expression
AU738838B2 (en) Compositions and methods for pulmonary gene delivery
WO1996027393A1 (en) A dry powder formulation for gene therapy
WO1996027393A9 (en) A dry powder formulation for gene therapy
WO1998010796A9 (en) Compositions and methods for pulmonary gene delivery
Guo et al. Nucleic acid delivery by lipid nanoparticles for organ targeting
Desigaux et al. Nonionic amphiphilic block copolymers promote gene transfer to the lung
RU2242970C2 (ru) Композиции полиэтиленимин: днк для аэрозольной доставки
Schreier et al. Liposomal DNA vectors for cystic fibrosis gene therapy. Current applications, limitations, and future directions
Natsume et al. Cationic liposome conjugation to recombinant adenoviral vector reduces viral antigenicity
Kinsey et al. Non-viral gene delivery to the lungs
Baradaran et al. A novel method for the development of plasmid DNA-loaded nanoliposomes for cancer gene therapy
Miller Nonviral liposomes
I Khatri et al. Patents review in siRNA delivery for pulmonary disorders
CN118717965A (zh) 一种核酸疫苗和核酸免疫佐剂共载的复合脂质纳米制剂及制备方法与用途
WO2025021740A1 (en) Nano-in-micro encapsulated therapeutic nucleic acid dry powder and pharmaceutical product containing said dry powder
KR101671864B1 (ko) 요오드화 오일을 함유하는 양이온성 에멀젼 및 바이러스 벡터의 유전자 전달 증진을 위한 이의 용도
Costabile et al. Emerging Pulmonary Delivery Strategies in Gene Therapy: State of the Art and Future Considerations
Kleemann Polyethylenimine-and lipid-based nanoparticles as gene and drug delivery systems for aerosol therapy to the lung
Benns Tailoring functional polymeric gene carriers
Sorgi Pharmaceutical considerations for cationic liposome-mediated gene delivery systems

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20050411

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060131

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090302

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090723